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Abstract: As pregnant women are at high risk of severe SARS-CoV-2 infection and COVID-19
vaccines are available in Switzerland, this study aimed to assess the willingness of Swiss pregnant
and breastfeeding women to become vaccinated. Through a cross-sectional online study conducted
after the first pandemic wave, vaccination practices and willingness to become vaccinated against
SARS-CoV-2 if a vaccine was available were evaluated through binary, multi-choice, and open-ended
questions. Factors associated with vaccine willingness were evaluated through univariable and
multivariable analysis. A total of 1551 women responded to questions related to the primary outcome.
Only 29.7% (153/515) of pregnant and 38.6% (400/1036) of breastfeeding women were willing to
get vaccinated against SARS-CoV-2 if a vaccine had been available during the first wave. Positive
predictors associated with SARS-CoV-2 vaccine acceptance were an age older than 40 years, a higher
educational level, history of influenza vaccination within the previous year, having an obstetrician
as the primary healthcare practitioner, and being in their third trimester of pregnancy. After the
first pandemic wave, Switzerland had a low SARS-CoV-2 vaccination acceptance rate, emphasizing
the need to identify and reduce barriers for immunization in pregnant and breastfeeding women,
particularly among the youngest and those with a lower educational level.
Keywords: SARS-CoV-2; coronavirus; COVID-19; pregnancy; breastfeeding; vaccine willingness
1. Introduction
In 2020, the outbreak of a novel coronavirus, the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), was declared a pandemic with more than 166 million con-
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firmed cases worldwide. In Switzerland, more than 680,000 people tested positive with
more than 10,000 deaths reported [1].
Pregnant women are considered a vulnerable population for SARS-CoV-2 infection.
Current evidence suggests that they are up to 70% more susceptible to infection. If infected,
they are also at greater risk of developing complications [2–4] such as admission to an
intensive care unit, mechanical ventilation, and death [5,6]. Increased risk of caesarian
section, iatrogenic prematurity, post-partum hemorrhage, preeclampsia, and miscarriage
have also been reported [7–11].
Currently, two SARS-CoV-2 mRNA vaccines approved by Swissmedic (the Swiss
authority for the utilization and surveillance of therapeutic products) are used in the vac-
cine campaign in Switzerland [12]. However, vaccines cannot curb epidemics without
widespread acceptance. The World Health Organization (WHO) has listed vaccine hesi-
tancy as one of the top ten threats to global health [13], especially for populations at risk.
In Switzerland, as in many countries, vaccination programs have already been established
to protect pregnant women and their infants from serious infections such as influenza and
pertussis. Both influenza and pertussis vaccines have proven to be effective in protecting
mothers and their newborns [14,15]. However, immunization rates for influenza and per-
tussis have been disappointingly low in Switzerland [16] mainly due to a lack of adequate
promotion and compliance [17]. Low uptake of vaccination in pregnancy has been reported
worldwide [18,19] with several studies identifying inadequate knowledge about the disease
threat; doubts about vaccine safety, efficacy, and benefits; and the lack of recommendations
from vaccine providers, as the main obstacles among pregnant women [20–22]. Maternal
characteristics may also play a role. Unemployment, younger age (<25 years old), and
high perceived stress have been associated with lower vaccination rates during pregnancy,
whereas a history of depression increased the likelihood of being vaccinated [23].
SARS-CoV-2 vaccination has recently been recommended in Switzerland for pregnant
women who have additional risk factors or are at high risk of exposure through their
work. This vaccination strategy may represent a barrier to the successful vaccination of
all members of this high-risk group, especially when compared to some countries where
pregnant women are routinely vaccinated or considered a priority group. This is a glaring
example of the need to better understand the many factors influencing the acceptance of
and access to vaccination, especially among more vulnerable populations such as pregnant
women to develop targeted information campaigns.
Thus, in a cross-sectional survey during the first wave of the pandemic, we investi-
gated COVID-19 vaccine willingness among Swiss pregnant and breastfeeding women if a
vaccine was available, as well as the factors contributing to their acceptance or hesitancy.
2. Materials and Methods
2.1. Study Population and Data Collection
This Swiss cross-sectional online study is part of a European multi-center study con-
ducted in several countries (Belgium, Ireland, Norway, The Netherlands, United Kingdom)
and approved by the Ethics Committee Research of UZ/KU Leuven (id: S63966). The
questionnaire used in Switzerland was available in German, French, and Italian. The goal
was to examine the overall impact of the SARS-CoV-2 pandemic on pregnant and breast-
feeding women (i.e., pregnancy/breastfeeding experience, life and professional habits,
mental health status, relationship with the healthcare system, medication use, and vaccine
perceptions during pregnancy/breastfeeding) [24]. The COVID-19 vaccine willingness of
pregnant and breastfeeding women included in the multi-center study has already been
published [25], and the Swiss rate was among the lowest, hence the need to investigate the
factors associated with vaccine acceptance in a Swiss-specific study.
In Switzerland, the online questionnaire was accessible from 18 June to 12 July 2020
through websites, forums, and social media (www.letsfamily.ch, www.swissmom.ch,
www.medela.ch, www.chuv.ch). All data were collected and processed anonymously. All
participants provided online informed consent prior to survey initiation.
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2.2. Study Population
To be eligible, Swiss women needed to be at least 18 years old and be pregnant at the
time of the survey or have breastfed within the past three months.
2.3. Variables
We collected information on sociodemographic characteristics (i.e., age, primary
language, marital status, working status, education level), medical history (i.e., gravidity,
parity, co-morbidities, smoking during pregnancy, main practitioner for the pregnancy
follow-up, clinical course of the neonate for breastfeeding mothers), exposure to SARS-
CoV-2 or presence in an at-risk setting (i.e., symptoms potentially related to COVID-19,
hospitalization related to COVID-19, testing by RT-PCR, serology or computed tomography,
living with someone who tested positive, co-habiting with an elderly person (>65 years
old)). The negative impact of the SARS-CoV-2 pandemic on the pregnancy/breastfeeding
experience, life habits, and work was assessed through participants graded answers: “yes”
or “rather yes”, grouped as “negative impact of the SARS-CoV-2 pandemic”; and “rather
no” or “no”, grouped as “no negative impact of the SARS-CoV-2 pandemic”. Mental health
status was assessed using validated screening tests including the Edinburgh Postnatal
Depression Scale for depression [26,27], the Generalized Anxiety Disorder 7-item Scale for
anxiety [28], and the Perceived Stress Scale for stress [29,30]. Information on vaccination
practices was obtained through a dichotomic question on vaccination against influenza
within the past year (yes or no) and multi-choice questions assessing their opinion on
influenza vaccine usefulness during pregnancy and breastfeeding, the fear of maternal and
fetal/neonatal side effects, and overall vaccination acceptance.
2.4. Main Outcomes
COVID-19 vaccine willingness of pregnant and breastfeeding women if a vaccine had
been available was evaluated through participants’ graded answers: “fully agree”, “rather
agree”, “rather disagree”, or “fully disagree”. Participants who “fully agree” or “rather
agree” were grouped as “willing to get vaccinated against SARS-CoV-2” and those who
“rather disagree” or “fully disagree” were grouped as “not willing to get vaccinated against
SARS-CoV-2” in the analysis.
2.5. Statistical Analysis
Baseline and medical characteristics, SARS-CoV-2 exposure (SARS-CoV-2 testing,
symptoms, and hospitalization), fears, impacts of the pandemic, mental health symptoms,
and vaccination habits were presented using descriptive statistics for both pregnant and
breastfeeding women. The prevalence of participants willing to get vaccinated against
COVID-19 was calculated.
The associations between variables of interest and the willingness to get vaccinated
against SARS-CoV-2 was measured by univariate and multivariate logistic regression
and were presented as crude odds ratios (OR) and adjusted odds ratios (aORs) with 95%
confidence intervals (95% CI). Variables with p > 0.10 in the univariate analysis were not
included in the multivariate model. The variables of interest were maternal age >40 years
old, educational level (dichotomized as higher than high school or not), professional activity
(dichotomized as active or not), primary language (French, German, Italian), maternal co-
morbidities (grouped into a single “any maternal co-morbidity” variable), testing positive
for SARS-CoV-2 infection (either by RT-PCR, serology, or CT-scan, grouped into a single
“tested positive for SARS-CoV-2” variable), living with someone >65 years old, having a
negative impact by the pandemic on the pregnancy/breastfeeding experience, life habits,
and work, experiencing symptoms of severe depression (EDS ≥ 13), anxiety (GAD-7 ≥ 15),
or high stress perceived (PSS ≥ 27) (grouped into a single variable), being vaccinated
against influenza in the past year, previous history of declining vaccination, and fear of
side effects related to vaccines (for the mother and the fetus/neonate). Variables specific
to pregnant women (pregnancy practitioner, current trimester of gestation, and fear of
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an adverse fetal outcome in case of maternal SARS-CoV-2 infection) were studied in a
supplementary multivariate model including only pregnant participants.
2.6. Missing Values
Maternal comorbidities were considered as absent if not reported, based on the as-
sumption that severe comorbidities are normally documented. Based on the hypothesis
of missing variables completely at random (MCAR), multiple imputations with chained
equations (10 replications) were performed to increase the power of comparisons for
missing values.
3. Results
A total of 2064 respondents participated in the survey (1161 using the French ques-
tionnaire, 868 using the German questionnaire, and 35 using the Italian questionnaire)
including 1501 breastfeeding and 563 pregnant women. Among them, 513 (24.9%) did
not answer the question relating to whether they were willing to get vaccinated against
SARS-CoV-2 if a vaccine was available. Thus, 75.1% (n = 1551) contributed to the analyses
addressing the primary aim of the study (1036 breastfeeding mothers and 515 pregnant
women) (Figure 1).
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3.1. Baseline Characteristics
Baseline characteristics are presented in Table 1. The median age of respondents was
33 years and the majority were married or cohabiting (79.8%; 1237/1551). A significant
proportion of women were healthcare providers (20.4%; 317/1551) or homemakers (9.0%;
139/1551). A high proportion of participants (46.5%; 721/1551) had an education level
above high school. Overall, 9.7% (151/1551) reported having co-morbidities.
Among the pregnant participants, the median gestational age was 28 weeks’ gestation
at the time of survey completion. Half of them were multigravida (275/515), among which
74.4% (204/274) and 18.2% (50/274) had one or more previous children respectively. More
than 90% (468/515) were under the care of an obstetrician. Among the breastfeeding
participants, 2.8% (29/1036) had their neonates hospitalized in an intensive care unit.
3.2. SARS-CoV-2 Exposure, Fears, and Beliefs
Data on SARS-CoV-2 exposure, fears, and beliefs are presented in Table 2. Almost
55% (850/1551) of participants reported having experienced symptoms potentially related
to SARS-CoV-2 within the 3 months preceding the survey. Only 10.9% (170/1551) of the
women had been tested for SARS-CoV-2 infection, among which 10.5% had a positive
result (18/170) through a PCR-based nasopharyngeal swab, serology, or CT-scan. Less than
1.0% (9/1551) reported having been hospitalized due to COVID-19. Only 1.2% (18/1551)
of participants reported living with someone older than 65 years old. Participants reported
that the COVID-19 pandemic had a negative impact on their pregnancy or breastfeeding
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experience in 35.3% (97/275) and 8.0% (41/512) of cases, respectively. According to
their responses, 11.0% (170/1551) of them experienced symptoms of severe depression
(EDS ≥ 13), anxiety (GAD-7 ≥ 15), or high stress (PSS ≥ 27) over the last four weeks. More
than half of pregnant women (53.4%; 275/515) declared that they feared an adverse fetal
outcome in case of maternal infection.
Table 1. Baseline characteristics and medical history of participants. Abbreviations: ENT, ear nose throat; IQR, interquartile
range; NICU, neonatal intensive care unit, HCP, healthcare provider.
Pregnant Women Breastfeeding Mothers Total
n = 515 (%) n = 1036 (%) n = 1551 (%)
Baseline characteristics
Maternal age (years)—median
(IQR) 33 (31–35) 33 (31–35) 33 (31–35)
>40 years 19 (3.7) 63 (6.1) 82 (5.3)
Marital status
Married/cohabiting 422 (81.9) 815 (78.7) 1237 (79.8)
Single/divorced/others 4 (0.8) 9 (0.9) 13 (0.8)
Unknown 89 (17.3) 212 (20.5) 301 (19.4)
Working status
Health care
provider 122 (23.7) 195 (18.8) 317 (20.4)
Employed other
than HCP 257 (49.9) 465 (44.9) 722 (46.6)
Student 3 (0.6) 7 (0.7) 10 (0.6)
Housewife 21 (4.1) 118 (11.4) 139 (9.0)
Job seeker 12 (2.3) 23 (2.2) 35 (2.3)
Unknown 100 (19.4) 228 (22.0) 328 (21.1)
Educational level
Less than high
school 9 (1.8) 20 (1.9) 29 (1.9)
High school 75 (14.6) 212 (20.5) 287 (18.5)
More than high
school 257 (49.9) 464 (44.8) 721 (46.5)
Unknown 174 (33.8) 340 (32.8) 514 (33.0)
Primary language
French 217 (42.1) 418 (40.4) 635 (40.9)
German 183 (35.5) 322 (31.1) 505 (32.6)
Italian 8 (1.6) 23 (2.2) 31 (2.0)
Other 18 (3.5) 61 (5.8) 79 (5.1)
Unknown 89 (17.3) 212 (20.5) 301 (19.4)
Maternal co-morbidities
Any comorbidity 51 (9.9) 100 (9.7) 151 (9.7)
Pulmonary 14 (2.7) 28 (2.7) 42 (2.7)
Cardio-vascular 6 (1.2) 11 (1.1) 17 (1.1)
Pregestational
diabetes 5 (1.0) 9 (0.9) 14 (0.9)
Thyroid
dysfunction 12 (2.3) 27 (2.6) 39 (2.5)
Oncologic 1 (0.2) 2 (0.2) 3 (0.2)
Hematologic 2 (0.4) 0 (0.0) 2 (0.1)
Auto-immune 2 (0.4) 4 (0.4) 6 (0.4)
Neurologic 3 (0.6) 4 (0.4) 7 (0.5)
Psychic 3 (0.6) 6 (0.6) 9 (0.6)
Digestive 3 (0.6) 7 (0.7) 10 (0.7)
Uro-genital tract 6 (1.2) 15 (1.4) 21 (1.4)
Cutaneous 2 (0.4) 4 (0.4) 6 (0.4)
ENT 0 (0.0) 1 (0.1) 1 (0.1)
Smoking 69 (13.4) 149 (14.4) 218 (14.1)
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Table 1. Cont.
Pregnant Women Breastfeeding Mothers Total
n = 515 (%) n = 1036 (%) n = 1551 (%)
Actual pregnancy or breastfeeding
Practitioner: Obstetrician 468 90.9 /
Midwife 13 8.3
Family physician 4 0.8
Gestation 1 240 46.6 /
>1 275 53.4
Parity 0 20/274 7.3 /
1 204/274 74.4
>1 50/274 18.2
Planned pregnancy 483 93.8 /
Gestational age—median (IQR) 28 (18-34) /
1st Trimester 79 (15.0)
2nd Trimester 194 (40.7)
3rd Trimester 241 (44.3)
Neonate hospitalized in NICU / 29 (2.8)
Table 2. SARS-CoV-2 exposure, fears, and beliefs. Abbreviations: PCR, polymerase chain reaction.
Pregnant Women Breastfeeding Mothers Total
n = 515 (%) n = 1036 (%) n = 1551 (%)
SARS-COV-2 exposure
Symptoms during the 3 last months 296 (57.5) 554 (53.5) 850 (54.8)
Hospitalized for COVID-19 2 (0.4) 7 (0.7) 9 (0.6)
Tested for SARS-CoV-2 infection 48 (9.3) 122 (11.8) 170 (10.9)
PCR on nasopharyngeal
swab 39 (7.6) 112 (108.0) 151 (9.7)
positive 5/39 (12.8) 6/112 (5.3) 11/151 (7.3)
negative 33/39 (84.6) 103/112 (92.0) 136/151 (90.1)
unknown 1/39 (2.6) 3/112 (2.7) 4/151 (2.7)
Serology 7 (1.4) 21 (2.0) 28 (1.8)
positive 3/7 (42.9) 2/21 (9.5) 5/28 (17.9)
negative 3/7 (42.9) 16/21 (76.2) 19/28 (67.9)
unknown 1/7 (14.2) 3/21 (14.3) 4/28 (14.3)
Scanner 2 (0.4) 2 (0.2) 4 (2.6)
positive 2/2 (100.0) 0/2 (0.0) 2/4 (50.0)
negative 0/2 (0.0) 2/2 (100.0) 2/4 (50.0)
Living with someone with symptoms 82 (15.9) 220 (21.2) 302 (19.5)
Living with someone tested positive 4 (0.8) 10 (1.0) 14 (0.9)
Living with someone > 65 years old 6 (1.2) 12 (1.2) 18 (1.2)
Negative impact of the COVID-19
pandemic on:
Pregnancy or breastfeeding experience 97 (18.8) 41 (4.0) 138 (8.9)
unknown 240 (46.6) 524 (50.6) 764 (49.3)
Life habits 350 (68.2) 700 (67.6) 1050 (67.7)
unknown 8 (1.6) 25 (2.4) 33 (2.1)
Work 295 (57.3) 394 (38.0) 689 (44.4)
unknown 100 (19.4) 320 (30.9) 420 (27.1)
Fear of an adverse fetal outcome 275 (53.4) /
Symptoms of severe depression, anxiety
or high stress perceived during the 1st
wave
53 (10.3) 117 (11.3) 170 (11.0)
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3.3. Vaccination Practices and Beliefs
Only 19.3% (85/440) of pregnant and 28.0% (249/891) of breastfeeding women were
vaccinated against influenza in the past year. Among the participants, 10.5% (163/1551) and
0.1% (2/1551) mentioned fear of potential consequences for their fetus/infant or themselves
respectively resulting from vaccination during pregnancy or breastfeeding. More than 20%
(324/1551) of them indicated usually declining influenza vaccination, and 7.5% (117/1551)
think the influenza vaccine is not needed during pregnancy or breastfeeding (Figure 2).
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3.4. Willingness to Get the SARS-CoV-2 Vaccine
Only 29.7% (153/515) of pregnant and 38.6% (400/1036) of breastfeeding women were
willing to get vaccinated against SARS-CoV-2 if a vaccine had been available during the
first wave. More specifically, 8.1% (127/1551) fully agreed, 27.5% (426/1551) somewhat
agreed, 40.4% (626/1551) somewhat disagreed, and 24% (372/1551) fully disagreed to get
vaccinated (Figure 2 and Table S1).
3.5. Factors Associated with SARS-CoV-2 Vaccine Willingness
Potential predictors of SARS-CoV-2 vaccine acceptance are shown in Table 3. So-
ciodemographic factors such as a maternal age above 40 years old (aOR 1.8 [1.1–3.2]), an
educational level higher than high school (aOR 1.5 [1.2–2.0]), and Italian as a primary
language (aOR 3.3 [1.4–8.0]) were associated with a higher rate of vaccine acceptance. On
the other hand, German-speaking participants were less likely to get vaccinated (aOR 0.7
[0.5–0.9]).
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Table 3. Factors associated with SARS-CoV-2 vaccine willingness among Swiss pregnant and breastfeeding women.
Abbreviations: aOR, adjusted odds ratio; CI, confidence interval; CT, computed tomography; OR, odds ratio; RT-PCR,








OR (95 % CI) p aOR (95% CI) p
N (%) N (%)
553 (35.7) 998 (64.3)
Baseline characteristics
Maternal age >40 years 42 (7.6) 40 (4.0) 2.0 (1.3–3.0) 0.003 1.8 (1.1–3.2) 0.028
Educational level > highschool 300 * (75.9) 421 * (65.6) 1.7 (1.3–2.2) <0.001 1.5 (1.1–2.0) 0.017
Professionally active 387 * (87.4) 652 * (83.6) 1.4 (1.0–1.9) 0.007 1.0 (0.7–1.5) 0.919
Primary language
French 238 (52.8) 397 (49.7) 1.1 (0.9–1.4) 0.295
German 159 * (35.3) 346 * (43.3) 0.7 (0.6–0.9) 0.005 0.7 (0.5–0.9) 0.015
Italian 19 * (4.2) 12 * (1.5) 2.9 (1.4–6.0) 0.005 3.3 (1.4–8.0) 0.007
Any maternal co-morbidity 58 (10.5) 93 (9.3) 1.1 (0.8–1.6) 0.457
Impact of the SARS-COV-2 pandemic
Tested positive for SARS-COV-2 (RT-PCR,
serology and/or CT) 9 (1.6) 3 (0.3) 5.5 (1.5–20.4) 0.011 3.3 (0.8–13.7) 0.095
Living with someone >65 years old 10 (1.8) 8 (0.8) 2.3 (0.8–6.7) 0.076 2.0 (0.7–6.1) 0.094
Negative impact of the pandemic on
Pregnancy 52 (19.9) 86 (16.3) 1.1 (1.0–1.2) 0.215
Life
habits 398 * (72.8) 652 * (67.2) 1.3 (1.0–1.7) 0.023 1.0 (0.8–1.4) 0.822
Work 244 (60.1) 445 (61.4) 1.0 (0.7–1.2) 0.672
Symptoms of severe depression, anxiety or
high stress 68 (12.3) 102 (10.2) 1.2 (0.9–1.7) 0.211
Vaccination habits and beliefs
Vaccinated against Influenza last year 197 * (41.1) 137 * (16.1) 3.6 (2.8–4.7) <0.001 2.1 (1.5–2.8) <0.001
Usually decline vaccination 30 (5.4) 294 (29.5) 0.1 (0.1–0.2) <0.001 0.2 (0.1–0.3) <0.001
Fear of side effects related to vaccines 51 (9.2) 114 (11.4) 0.8 (0.6–1.1) 0.179
Supplementary model including
pregnancy-related variables
(tested only in pregnant women,
N = 515)
N (%) N (%) OR (95%CI) p aOR (95%CI) p
153 (29.7) 362 (60.3)
Follow-up by an obstetrician 144 (94.1) 324 (89.5) 1.9 (0.9–4.0) 0.101 3.6 (1.2–11.2) 0.027
Gestational age
T1 25 (16.3) 54 (15.0) 1.1 (0.7–1.9) 0.691
T2 47 (30.7) 147 (40.7) 0.6 (0.4–1.0) 0.033 0.6 (0.4–0.9) 0.015
T3 81 (52.9) 160 (44.3) 1.4 (1.0–2.0) 0.074 1.8 (1.1–2.7) 0.018
Fear of an adverse fetal outcome in case of
infection 75 (49.0) 200 (55.3) 0.9 (0.8–1.0) 0.196
* Multiple imputations on missing values.
Having had the influenza vaccination in the past year was a positive predictor for
SARS-CoV-2 vaccine acceptance (aOR 2.1 [1.5–2.8]). Women who usually declined influenza
vaccination were less likely to be willing to get the SARS-CoV-2 vaccine (aOR 0.2 [0.1–0.3]).
When assessing the impact of the SARS-CoV-2 pandemic, none of the variables showed
statistically significant influence on the willingness to get vaccinated. However, a trend
toward COVID-19 vaccine willingness can be observed among women having a positive
diagnosis of SARS-CoV-2 (aOR 3.3 [0.8–13.7] and living with someone older than 65 years
old (aOR 2.0 [0.7–6.1]).
Among the pregnant participants, those who had an obstetrician following their
pregnancy (aOR 3.6 [1.2–11.2]) and who were in their third trimester of pregnancy (aOR
1.8 [1.1–2.7]) were more likely to be willing to receive the SARS-CoV-2 vaccine. On the
other hand, being in their second trimester of pregnancy was associated with a higher
SARS-CoV-2 vaccination refusal (aOR 0.6 [0.4–0.9]).
4. Discussion
Our results demonstrate that in Switzerland, only one-third (35.7%; 553/1551) of
pregnant and breastfeeding women that participated in the survey were willing to get a
SARS-CoV-2 vaccine during the first wave of the pandemic if one had been available. The
positive predictors for SARS-CoV-2 vaccine acceptance among all participants were an age
older than 40 years, a higher educational level, speaking Italian as their primary language,
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and having been vaccinated against influenza in the previous year. On the other hand,
speaking German and usually declining influenza vaccination were negative predictors.
Regarding pregnant participants, having an obstetrician following their pregnancy and
being in their third trimester of pregnancy were two positive factors associated with the
willingness to be vaccinated against SARS-CoV-2, whereas being in their second trimester
of pregnancy was a negative predictor. No association was found between maternal
co-morbidities and the participants’ willingness to get vaccinated.
4.1. Interpretation
Our study shows that despite Switzerland being among SARS-CoV-2 high incidence
countries during the first wave with a particularly negative impact on pregnancy and
breastfeeding experience [24], it has a low rate of SARS-CoV-2 vaccination acceptance. The
results from our survey of Swiss women were among the lowest when compared to a
recent survey conducted in 16 countries that showed a SARS-CoV-2 vaccine acceptance rate
among pregnant women of 52.0%, with responses varying substantially between countries
(28.8–84.4%) [31]. An American cross-sectional survey showed a rate of 41% of SARS-CoV-2
vaccine acceptance among pregnant women [32]. The low percentage of Swiss pregnant
women willing to get the SARS-CoV-2 vaccine that we observed is consistent with the rather
low influenza and pertussis immunization rates in Switzerland previously mentioned [16].
We also identified variability in SARS-CoV-2 vaccine acceptance between different regions
of Switzerland. This has already been observed with Swiss-German women being more
reluctant to get their children vaccinated [33,34]. In contrast, the part of Switzerland most
affected by SARS-CoV-2, the Italian part, seems to have a higher rate of vaccine acceptance
than the other parts of Switzerland, although fewer Italian speaking women were included,
and these results should be interpreted with caution.
In this Swiss sub-analysis, the proportion of breastfeeding women willing to be
vaccinated was higher than that of pregnant women (38.6% vs. 29.7%). This difference
was also found in all countries included in the European study of which these data are a
part, with a difference of up to +25% for the UK [25]. These results support that “vaccine
hesitancy” may be even more common during pregnancy, which may be related to an
overall greater reluctance to use medicines during pregnancy.
When assessing factors influencing SARS-CoV-2 vaccine willingness among pregnant
women, our results are consistent with another study identifying older age and higher
educational level as positive predictors [31]. The same observations have been made for
acceptance of the pertussis and influenza vaccines [23,31]. The positive correlation that
we observed between SARS-CoV-2 vaccine willingness and having received the influenza
vaccine during the previous season has also been found in a recent study evaluating
pregnant women [32]. In addition, we identified that being in the second trimester of
pregnancy might be a negative predictor for SARS-CoV-2 vaccine acceptance, suggesting
a potential fear for induced fetal malformations. This is consistent with several studies
identifying fear for any potential harmful side effects of the vaccine on their fetus or
infant as well as concerns regarding safety and effectiveness as major reasons for vaccine
reluctance [22,31,32]. Concerns about teratogenicity would be more likely in the first
trimester, as second trimester exposures do not cause embryopathy. Here, patients who
responded to the survey as being in the second trimester correspond to those who were in
the first trimester at the time of the first wave, so our results may suggest that their fear of
teratogenicity may be higher in early pregnancy and not necessarily in the second trimester.
In contrast, we did not find an association between having experienced symptoms of severe
depression, anxiety, or high stress in the weeks prior to the survey and the willingness to get
the SARS-CoV-2 vaccine. This is not in line with a previous study where pregnant women
with a history of major depressive disorder and moderate anxiety were significantly more
likely to get influenza and pertussis vaccines [23]. However, at the time of the survey, no
SARS-CoV-2 vaccine was yet available, and thus, no information was available regarding
its safety or effectiveness in general and in the pregnant population, which may explain
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the reluctance of anxious or depressed women who may need safety information before
accepting the vaccine. This might also have influenced participants who did not answer
the question about SARS-CoV-2 vaccination acceptance, as the ambivalence toward this
vaccine is still very strong. It is also interesting to note that while most participants showed
acceptance of influenza vaccines, a much smaller percentage actually received it. This
might question the access of Swiss breastfeeding and pregnant women to vaccines and
how healthcare workers might play a role in it.
Our observations suggest that more than a specific reluctance toward the SARS-CoV-2
vaccine, it is one’s personal opinion on vaccination during pregnancy in general that might
prevent Swiss pregnant and breastfeeding women from getting vaccinated. Hence, it is our
hypothesis that SARS-CoV-2 and influenza or pertussis vaccines are avoided for similar
reasons: mainly the lack of recommendation by healthcare professionals and the lack of
compliance by pregnant women. Until the end of May 2021, Switzerland has made access
to vaccines challenging, even for women that might want to be vaccinated, which could
represent a barrier for vaccine acceptance. Furthermore, the ongoing debates over SARS-
CoV-2 vaccines may have a negative influence on the willingness of pregnant women
to become vaccinated. This emphasizes the need to improve access to vaccination for
pregnant women as well as knowledge and acceptance of immunization during pregnancy
among healthcare workers and pregnant/breastfeeding women.
4.2. Strengths and Limitations
In terms of temporality, our study explored the experience of Swiss pregnant women
during the first wave of the SARS-CoV-2 pandemic. Our study included a large number of
participants from different parts of Switzerland, was conducted in three official languages,
and is the first to address the question of SARS-CoV-2 vaccine willingness in the country.
Selection bias might have occurred as the proportion of participants who are professionally
active and highly educated was higher than the general population of Swiss pregnant
women [35,36]. This could have led to an increased vaccination acceptance rate, as highly
educated women tend to have a higher acceptance of vaccination, which would mean
that the vaccine willingness in the overall perinatal population might be even lower than
that reported here. The survey was conducted online and, although most Swiss women
have good access to the internet, those that rely more on online resources may have come
across the online survey more often when looking for information about their pregnancy
or breastfeeding. Women hospitalized or severely ill might not have had the opportunity
to participate. This could have biased the association between SARS-CoV-2 exposure and
the participants’ willingness to get vaccinated toward the null. In addition, as only 5%
of women declared speaking another language in our survey, we might have an under
representation of the immigrant population.
Another limitation might be the overrepresentation of French-speaking participants,
which could be explained by the CHUV (Centre Hospitalier Universitaire Vaudois, univer-
sity hospital of the largest French-speaking canton) leading the present study. Since some
studies have shown an increased vaccination acceptance among the French-speaking part
of Switzerland, this could have overestimated the rate of SARS-CoV-2 vaccine willingness
in our study. Overestimation of SARS-CoV-2 vaccination acceptance could have also hap-
pened since a high percentage of participants were healthcare workers, more likely to be
exposed to SARS-CoV-2 positive patients, and thus, more prone to being immunized.
Factors reported to be associated with SARS-CoV-2 vaccine willingness, considered in
other studies, were not measured [31,32]. Those include socioeconomic status; perceived
risk of SARS-CoV-2 (likelihood of infection, self or infant); opinion on the importance to
public health to get a vaccine and for the majority of people to get vaccinated; compliance
with preventive measures; monitoring of SARS-CoV-2 news and updates; trust and satis-
faction with health authorities; as well as trust in science. Further surveys including those
variables would be needed to better specify the factors influencing SARS-CoV-2 vaccination
acceptance among Swiss pregnant women.
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Finally, this survey was conducted at a time when no SARS-CoV-2 vaccine had yet
been accepted by Swissmedic nor recommended for pregnant women. This could represent
an important bias, since participants were asked if they would accept a potential vaccine
without information about its efficiency and safety. Since this survey, the first randomized
controlled trial of SARS-CoV-2 vaccination in pregnancy has been initiated [37]. Addition-
ally, following the example of several other countries, the Swiss Society for Gynecology
and Obstetrics (SSGO) along with the Federal Public Health Office (OFSP) has recom-
mended, up until the end of May 2021, SARS-CoV-2 vaccination during the second and
third trimester for pregnant women at high risk of developing complications or at high risk
of exposure [38]. Recent studies also showed robust immune responses and efficient pas-
sage of antibodies to newborns after SARS-CoV-2 vaccination of pregnant women [39,40],
unlike transplacental immunization through infected mothers, which seems to be less
effective [41]. As new guidelines and more data on vaccinated pregnant women become
available every day [42], willingness to become vaccinated might evolve, and new studies
are urgently needed.
5. Conclusions
Our study suggests disappointing SARS-CoV-2 vaccine willingness among Swiss
pregnant and breastfeeding women, emphasizing the need to identify and reduce barriers
toward immunization. Inclusion of pregnant women in clinical trials, improving access
to vaccines, and providing tailored information for pregnant and breastfeeding women,
especially for those of younger age with a lower educational level, are crucially needed to
protect them from SARS-CoV-2 and other viral threats ahead.
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